Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 5/20 | 0.48 |
| ▸ | HTR1A | P08908 | 5/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1335775 | 1.00 | SLC6A4 (0.48) | SLC6A4HTR1ASLC6A2SLC6A3MEN1 | |
| SCHEMBL1334738 | 0.84 | SLC6A4 (0.48) | SLC6A4HTR1ASLC6A2SLC6A3SIGMAR1 | |
| SCHEMBL1333470 | 0.81 | SIGMAR1 (0.47) | SLC6A4SIGMAR1 | |
| SCHEMBL6491789 | 0.79 | SLC6A4 (0.66) | SLC6A4HTR1ASLC6A2SLC6A3KMT2A | |
| SCHEMBL6491784 | 0.79 | SLC6A4 (0.66) | SLC6A4HTR1ASLC6A2SLC6A3KMT2A | |
| SCHEMBL1513406 | 0.79 | SLC6A2 (0.49) | SLC6A4SLC6A2SLC6A3SIGMAR1 | |
| SCHEMBL1733578 | 0.79 | UTS2R (0.59) | SLC6A4HTR1AMEN1KMT2ASIGMAR1 | |
| SCHEMBL1733581 | 0.79 | UTS2R (0.59) | SLC6A4HTR1AMEN1KMT2ASIGMAR1 | |
| SCHEMBL1333981 | 0.78 | SLC6A4 (0.50) | SLC6A4HTR1ASLC6A2SLC6A3SIGMAR1 | |
| SCHEMBL1333977 | 0.78 | SLC6A4 (0.50) | SLC6A4HTR1ASLC6A2SLC6A3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350068-B1 | UREA DERIVATIVES OF SUBSTITUTED NORTROPANES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INT (DE) | 2017-08-30 | — | — | EP | disclosed |
| EP-2350068-B1 | UREA DERIVATIVES OF SUBSTITUTED NORTROPANES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INT (DE) | 2017-08-30 | — | — | EP | disclosed |
| EP-2318403-B1 | Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INT (DE) | 2015-12-23 | — | — | EP | disclosed |
| EP-2318403-B1 | Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INT (DE) | 2015-12-23 | — | — | EP | disclosed |
| US-8829027-B2 | Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-09 | — | — | US | disclosed |
| US-8829027-B2 | Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-09 | — | — | US | disclosed |
| US-8829027-B2 | Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-09 | — | — | US | disclosed |
| US-8609690-B2 | Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-17 | — | — | US | disclosed |
| US-20120115853-A1 | Aryl- and Heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20120115853-A1 | Aryl- and Heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20110275595-A1 | Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | US | disclosed |
| US-20110275595-A1 | Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | US | disclosed |
| EP-2350068-A2 | UREA DERIVATIVES OF SUBSTITUTED NORTROPANES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | Boehringer Ingelheim International GmbH (DE) | 2011-08-03 | — | — | EP | disclosed |
| EP-2318403-A1 | ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF SUBSTITUTED NORTROPANES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | Boehringer Ingelheim International GmbH (DE) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010046445-A2 | UREA DERIVATIVES OF SUBSTITUTED NORTROPANES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010046445-A2 | UREA DERIVATIVES OF SUBSTITUTED NORTROPANES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010023161-A1 | ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF SUBSTITUTED NORTROPANES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-04 | — | — | WO | disclosed |
| WO-2010023161-A1 | ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF SUBSTITUTED NORTROPANES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115853-A1 | Aryl- and Heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use | HSD11B1, HSD11B2, HSD17B1 | SLC6A4 1594/4885HTR1A 416/4885SLC6A2 668/4885 |
| US-20110275595-A1 | Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use | HSD11B1, HSD3B1, HSD11B2 | SLC6A4 661/4885HTR1A 385/4885SLC6A2 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.